Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 4.51 and last traded at GBX 4.92, with a volume of 558574 shares. The stock had previously closed at GBX 5.
Allergy Therapeutics Price Performance
The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The firm has a fifty day moving average price of GBX 5.87 and a two-hundred day moving average price of GBX 8.46. The stock has a market capitalization of £311.88 million, a P/E ratio of -5.08, a P/E/G ratio of -30.70 and a beta of 0.83.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
- Copper Is the AI Trade No One Priced In—3 Miners With the Most to Gain
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
